{"name":"Ascletis Pharmaceuticals Co., Ltd.","slug":"ascletis-pharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ASC09F","genericName":"ASC09F","slug":"asc09f","indication":"Other","status":"phase_1"},{"name":"ASC11 tablets","genericName":"ASC11 tablets","slug":"asc11-tablets","indication":"Other","status":"phase_1"},{"name":"ASC18","genericName":"ASC18","slug":"asc18","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ASC40","genericName":"ASC40","slug":"asc40","indication":"Chronic hepatitis B infection","status":"phase_3"},{"name":"ASC41","genericName":"ASC41","slug":"asc41","indication":"Non-alcoholic steatohepatitis (NASH)","status":"phase_1"},{"name":"ASC40 tablets","genericName":"ASC40 tablets","slug":"asc40-tablets","indication":"Chronic hepatitis B infection","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ASC22","genericName":"ASC22","slug":"asc22","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_2"}]}],"pipeline":[{"name":"ASC09F","genericName":"ASC09F","slug":"asc09f","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC11 tablets","genericName":"ASC11 tablets","slug":"asc11-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC18","genericName":"ASC18","slug":"asc18","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC40","genericName":"ASC40","slug":"asc40","phase":"phase_3","mechanism":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"ASC41","genericName":"ASC41","slug":"asc41","phase":"phase_1","mechanism":"ASC41 is a thyroid hormone receptor beta (THRβ) agonist that modulates lipid metabolism.","indications":["Non-alcoholic steatohepatitis (NASH)","Hypercholesterolemia"],"catalyst":""},{"name":"ASC22","genericName":"ASC22","slug":"asc22","phase":"phase_2","mechanism":"ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells.","indications":["Non-small cell lung cancer (NSCLC)","Hepatocellular carcinoma (HCC)"],"catalyst":""},{"name":"ASC40 tablets","genericName":"ASC40 tablets","slug":"asc40-tablets","phase":"phase_3","mechanism":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.","indications":["Chronic hepatitis B infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQUU0xT0NOUjloUDNsYXlBSUFIZ1BvUWpybTBlMWM5NXk4SzN1b3RoM1Z3cmQ4NVNHZFJrM1hSOWdYalZYQnhqeUtubEJFY2tqdUk2LV9SMnZMcU5ncXFZTDl1NnQ0elg5NGYyVG5jT3RleFNpSmJSMFdwU1RtRUxmcEtmeUR4c3dOZHc0eXZmSmIyQm5KM3M3WTVMNXFZYUloNWNYc1lFRGk1NnJpWHV3dGJ2NWp0TXRaTXpkU1NKdVFtc1gwRlEw?oc=5","date":"2026-04-08","type":"pipeline","source":"BioPharma APAC","summary":"Ascletis Pharma Inc. Advances Oral GLP 1 And Amylin Combination For Obesity Treatment - BioPharma APAC","headline":"Ascletis Pharma Inc. Advances Oral GLP 1 And Amylin Combination For Obesity Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPNV9hYk5NeW5Ya3ZPMzdFbW5BMHJkSnJVQ3NRT1NOWURidkxrRUJZTDBVVlZrb3FNV0FaNkZSWTEzWmZLRVdtSlVTelFjY0Q4TFdGNWt1LTRUSjc4UnRWMkNlb09jWERkLWF0TWtkUm1wbUJKcXlhRUk2MUt3Nkl4cTRwRWlrOFJ2Nk1FQ1dzRzFab0d1djh4SVptMA?oc=5","date":"2026-01-20","type":"pipeline","source":"The Pharma Letter","summary":"Ascletis lines up once-monthly triple agonist ASC37 - The Pharma Letter","headline":"Ascletis lines up once-monthly triple agonist ASC37","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcmV3RXdxbDFMZFE1UlIxbjdDNEZiYVBSWXpRZXZMY3I4bGdQdk9DRm93YnRnQWw3aUpIb1pmUER1Z1FmR3VHNmtNUFVmQ001cVctSV9PZDgyaVZNQkYyQldKR25jUElPY3hucFU3alZiUWxjQ203Y3J5QTI3elpCb19RUmRuNkdiYmhmV2dSNENCVDBLUHhhM2V6WERJSFJUQVFjUHd0TTZFdllpb25aUWNrYjVDWXJrR0I2MlAySjdpelVKLWlpZmtDcGpfS05OaGxuTGhuQQ?oc=5","date":"2025-12-15","type":"pipeline","source":"European Pharmaceutical Review","summary":"AI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential - European Pharmaceutical Review","headline":"AI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxORVN6ZWQ0eTVkRUh6SDlTOXVqTzc2eXVRNE5NcjlYVWtDZEs1RDNKRkdSZGJuTlpIajBsN0lEa2tmMjVmTzlPUi1ISnd6TkJjRkhUcnh3aUFPNGVVTjFkQ1g3NnF0N3d1bUVrd1FPdjVJMlEwZmE1Rm5ocGhxVkdJZmZNQ2poSTF3T21VbkJvbEg4ZUk4bjFILXBlTXQtQVBhMzk4d3JzZEp6eFEwOEg1RG9KX04?oc=5","date":"2025-12-08","type":"trial","source":"Fierce Biotech","summary":"China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study - Fierce Biotech","headline":"China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPU0Rfc3liZEh3UEFKVmJZdzZDUVRJdlhBMm1GV1dWUkhnOTA1MHRBZ2lfckxBMVE5V2hUSkY3c24xRTItQS1jLVd3X29xTHlTcnpwLW1mVmMtZjVEVkFWRTdQcldPblhIVEVHY0hvTVNsSkMzSG83NUQtWGFZTzRNVWxGT2xEWmxpZFRSdXNFdktHdWFFSmFNOF9tQlBGcTNQeXZjSlo2TVAxVnFEWWJmM1g4SUU4bmZTdFVrYVNMUGE?oc=5","date":"2025-12-08","type":"trial","source":"TechTarget","summary":"Ascletis announces phase 2 data for its oral GLP-1 candidate - TechTarget","headline":"Ascletis announces phase 2 data for its oral GLP-1 candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQRGd0WEJSWUtLWm03dkZnczc5N2pZZ2Ytb0FOb282WFhVcUdLZGlzYjBYSHozUmtjSkh5QkN6VTBJYnk1ZFliVlBmODFBUFBQRGs0T0M4RTZZVklBaURrV2pVcVIzcDdKUEEyQ2pHY3E5OXllbDlza2pQMlpjdE54VThBN0hjbmRzeWp5aWZtQ1BmQjJUUl9RMEVaamQybXdEZEVCTS1jMjVTVmpKOUNB?oc=5","date":"2025-12-08","type":"trial","source":"Bloomberg.com","summary":"China’s Ascletis Shares Surge on Oral Weight-Loss Drug Data - Bloomberg.com","headline":"China’s Ascletis Shares Surge on Oral Weight-Loss Drug Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOSVRxQXlnRFlIWGFWNm56bFV0cGtxcGh3cGU4Y25aWDA4WUM1N250VF82a2FabmN1UU1nVlpqb2ZLaEp6cVRwaUs5cHM3WnZaVTkwdmRKd2J6Vm5yRDFjQUZjN19tX1JzRG9MaUg0ZzBUYzFRV2tBQXV2dWVobzFEcw?oc=5","date":"2025-11-14","type":"trial","source":"Yahoo Finance","summary":"Why Ascletis Pharma (SEHK:1672) Is Up 45.4% After Unveiling New Obesity Drug Data and US IND Plans - Yahoo Finance","headline":"Why Ascletis Pharma (SEHK:1672) Is Up 45.4% After Unveiling New Obesity Drug Data and US IND Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOeU42MVNta3JiSTBxc3djZ1B2d0xwMVhmcERuUDIwQV9jV1AzRU15ZTJTZ2FMOGZvTjV6NWUwS2Q0N2ZMOUV3M25Janc5dWNYTkNQLVJ1blM5TVctQS1sYm1Telo5QmVQUzRheWNNZi1ZazRjUnJqUjNNWndjZ1dGR0c3VHF5b052UllvTXYzbUU2VGhYcTN0UjdVcXdjaTRUdWp6YzdYUW9BYUlTcUZza2NTZEExelV2MzlubTZoR1hmV2R1OGRCR0JHcV82R2htZ0tPSEtDV0NlYkhhUUlaTHBYeWpSQXN4NXNDbg?oc=5","date":"2025-09-25","type":"trial","source":"Pharmaceutical Executive","summary":"Ascletis’ Muscle-Preserving Weight Loss Drug Candidate Displayed Significant Improvement in Body Weight Reduction in ASC47-103 Study - Pharmaceutical Executive","headline":"Ascletis’ Muscle-Preserving Weight Loss Drug Candidate Displayed Significant Improvement in Body Weight Reduction in ASC","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-22","type":"regulatory","source":"South China Morning Post","summary":"Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect - South China Morning Post","headline":"Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOeGNjZnQzQlJ4VTQwbHl1aFdwb0R1VW9WSFJ0OEZyYUJjclFXd2UwYkIwNDB5S1V6SGhmTnBsVWgycHpkRnBRcXUxaEJJM1dqRUtqS2V2TndOWUJPWkN2Rlo5cU95MEMzQnJDMkJtU0pZMDRDSG9yOTlUU2psWXdCRndaYkNkQzVmZUtfQ24xQy14ODJiQkIxQkNLb2k5U05nU0QxMDVnNzNQdG5rdmNrWG1Xajc?oc=5","date":"2025-06-04","type":"trial","source":"Fierce Biotech","summary":"Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators - Fierce Biotech","headline":"Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOWDJPTkdZbjU5NG9VVk9ya1ZIRll6NUNRNGVvZWNoUURES3JuR0FGckdmLXJlSW5Fem5fYzFma29jdmhzUDE5RW5BbzQ0c2Zsc0tTc3pLTUhRSDdtQllTRFE5Y25rZUVURFVVVXItMGRZUUVZdk9XZ01UNkxpdG1wNEJyZUF5b21QVHc4dF9R?oc=5","date":"2025-06-04","type":"pipeline","source":"pharmaphorum","summary":"Ascletis says oral acne drug shows \"exceptional efficacy\" - pharmaphorum","headline":"Ascletis says oral acne drug shows \"exceptional efficacy\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNblhYaFFETW8zVGd1UzNzU2Zwc0dIR0dZMlFsM0Z1UTBfMXhlQW12QnJVenFTT0RfRjYzRklqazh5Q25zc2g5X3hVaE0tbzJFYU5VWHpQSU0yYjZERnNWUHhhMGw0SnJWeGNuMWJld3ptTFFMQXV4Um5CTlFlZ0FmRGVRWHhMQjh5ZHNmaVE0SmRpZG44Vkhoai1YdTZUNU9iMUlTN3ZPc2tUMXdTNWtyaFMxRlU3M2xSdGJVdVBEenFXRzlRNUpQTVJLelBYZw?oc=5","date":"2022-12-29","type":"pipeline","source":"Reuters","summary":"Viking Therapeutics accuses Chinese co of stealing fatty liver disease drug secrets - Reuters","headline":"Viking Therapeutics accuses Chinese co of stealing fatty liver disease drug secrets","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":4,"phase_3":2,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}